Substance/Medication-Induced Psychotic Disorder

Clinical picture

• Psychosis emerges during intoxication or within a month of withdrawal, with severity clearly exceeding what the agent's usual effects would produce.
• Stimulant psychosis features persecutory delusions, tactile hallucinations of insects on or under the skin, and extreme hypervigilance with clear orientation.
• Cannabis-related psychosis brings paranoia, ideas of reference, and depersonalization, most often in high-potency or synthetic cannabinoid users.
• Alcohol-related hallucinosis produces vivid auditory hallucinations with an intact sensorium, distinguishing it from the clouded state of delirium tremens.
• Medication causes include corticosteroids, anticholinergics, levodopa, interferon, isotretinoin, chloroquine, and high-dose prescription stimulants.
• Agitation, hyperthermia, and violence risk peak in stimulant and synthetic cannabinoid presentations and drive most emergency department contacts.

Criteria snapshot

• Prominent delusions or hallucinations that developed during or soon after substance intoxication, withdrawal, or exposure to a medication.
• The implicated substance or medication must be capable of producing the symptoms, established by history, physical examination, or laboratory findings.
• Not better explained by an independent psychotic disorder, which is suggested by symptoms preceding use or persisting well beyond acute withdrawal.
• The symptoms do not occur exclusively during delirium and cause clinically significant distress or functional impairment.
• Specify the substance, whether onset occurred during intoxication or withdrawal, and code with or without a comorbid substance use disorder.

Neurobiology

• Stimulants flood striatal synapses with dopamine through transporter reversal, producing the closest available pharmacologic model of positive symptoms.
• Repeated stimulant exposure sensitizes mesolimbic dopamine release, so psychosis recurs faster and at progressively lower doses with each episode.
• THC acts at CB1 receptors on GABAergic interneurons and disrupts cortical synchrony; potency and synthetic full agonists drive the greatest risk.
• NMDA antagonists such as ketamine and phencyclidine reproduce positive, negative, and cognitive symptoms, supporting the glutamatergic model of psychosis.
• Alcohol withdrawal psychosis reflects glutamate rebound after chronic GABAergic suppression, with thiamine deficiency compounding the vulnerability.
• Polygenic risk for schizophrenia is elevated among those whose substance-induced psychosis later converts, indicating an unmasked underlying liability.

Psychology

• Users often continue the substance to relieve the distress the psychosis creates, closing a self-reinforcing loop that blocks any spontaneous recovery.
• Sleep deprivation during stimulant binges is an independent psychotogenic factor, and restoring sleep alone resolves many milder presentations.
• Attribution matters clinically: patients who see the drug as the cause engage with abstinence, while those who do not relapse into psychosis quickly.
• Childhood adversity and trauma exposure raise both substance use and psychosis proneness, so the two conditions share upstream risk.
• Denial is reinforced by long stretches of use without psychosis, which undermines the credibility of abstinence advice at exactly the wrong moment.

Differential & comorbidity

• A primary psychotic disorder is suggested by symptoms preceding substance use, persistence beyond a month of abstinence, or a strong family history.
• Delirium is separated by fluctuating attention and disorientation, whereas substance-induced psychosis characteristically leaves the sensorium clear.
• Consider medical causes uncovered by heavy use: head injury, HIV, hepatic encephalopathy, thiamine deficiency, and endocarditis in injection drug users.
• Roughly a quarter of cases convert to schizophrenia, with cannabis-induced episodes carrying the highest rate, so follow these patients for years.
• Substance use disorder, PTSD, mood disorders, and antisocial or borderline traits are frequent comorbidities and set the intensity of aftercare.

Pharmacologic treatment

• Manage acute agitation with lorazepam 1-2 mg first in stimulant and withdrawal states, since benzodiazepines are preferred over antipsychotics here.
• Short-course antipsychotics such as olanzapine 5-10 mg or haloperidol 2-5 mg control persistent psychosis; watch QTc and seizure threshold.
• Alcohol withdrawal requires symptom-triggered benzodiazepine dosing guided by CIWA-Ar, plus thiamine 500 mg IV given before any glucose load.
• Taper the antipsychotic within weeks to a few months once psychosis clears, since indefinite maintenance implies a primary psychotic disorder instead.
• Treat the underlying use disorder directly with naltrexone, buprenorphine, or contingency management, which has the strongest stimulant evidence.

Psychotherapy

• Motivational interviewing builds commitment to abstinence during the window when the psychotic episode itself has made consequences vivid.
• Contingency management with escalating incentives remains the most effective psychosocial treatment for stimulant use disorder.
• Integrated dual-diagnosis treatment outperforms parallel or sequential care by addressing psychosis and substance use within one team.
• CBT for substance use identifies high-risk situations, builds refusal skills, and installs a written relapse prevention plan.
• Family involvement and community reinforcement approaches improve retention and supply collateral information about ongoing use.

Adjunct options

• Obtain expanded urine toxicology, since standard panels miss synthetic cannabinoids, cathinones, and many designer stimulants entirely.
• Observe for at least 24 to 48 hours before committing to a diagnosis, because most substance-induced psychosis improves substantially in that window.
• Re-evaluate at 1 month and 6 months of abstinence, since persistent symptoms reclassify the case as a primary psychotic disorder.
• Use ASAM criteria to set residential versus outpatient level of care, and provide harm reduction including take-home naloxone.
• Document the specific agent and its temporal relationship to symptoms, because this diagnosis is frequently revised by later clinicians.

Clinical pearls

• Symptoms preceding use, or persisting a month past abstinence, mean a primary psychosis.
• About one in four substance-induced psychoses converts to schizophrenia.
• In stimulant toxicity reach for benzodiazepines before antipsychotics.